Published Date: 21 Oct 2024
In confirmatory trial, antibody-drug conjugate failed to improve OS versus chemotherapy
Read Full NewsAs part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.
ALS expert Sabrina Paganoni, MD, PhD, provided follow-up commentary on promising phase 1 data from the LUMINA trial testing Amylyx’s novel agent AMX0114 in patients with early-stage ALS.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!
Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.
4 Psychiatry Headlines You Missed in December 2025
6 Nephrology Headlines You Missed in December 2025
Residential Neighborhood Disadvantage May Lower Kidney Transplant Access
1.
Outcomes in Resected Melanoma Influenced by Timing of Recurrence
2.
Could semaglutide be used to treat addiction in addition to obesity?
3.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
4.
King Charles' Cancer; COVID Vax Now or Later; Was RFK Jr. a Drug Dealer?
5.
New BCMA-Directed Therapies Show Promise in Multiple Myeloma
1.
Immuno-Oncology in Daily Practice: Transforming Cancer Care One Patient at a Time
2.
The Science Behind Imatinib: How It Targets Cancer Cells
3.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
4.
The Pros and Cons of Using Cyclophosphamide in Cancer Treatment
5.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation